muc-1 prr patent, page-3

Here is a start:

http://www.cancer.gov/drugdictionary/

'MUC-1 synthesis and secretion are features of glandular epithelial tissues; MUC-1 is overexpressed in lactating breast and in breast, ovary, lung, and prostate malignancies'

At the August investor presentation, Rogers touched on the possibility of Oncologists using Cvac for cancer treatment other than Ovarian Cancer. In the last letter to shareholders Ata has mentioned the total US cancer market.

The potential is enormous if Cvac passes its trial end points. And we now know the US FDA is taking a more open view on immunotherapy treatments and how their success should be measured.

Regards

dc